Live data · NADAC + Part D CY24 · reviewed daily

Aamlodipine and Olmesartan Medoxomil (Amlodipine and Olmesartan Medoxomil)

First FDA approval2025-02-14
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$0.319/unit
2 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.319
Across all dosage forms in distribution.
Highest NADAC
$0.319
Range is tight.
Plans with PA
0 / 329
Zero PA friction across surveyed plans.

Questions a plan sponsor actually asks.

FAQPage schema7 entries indexed · 4 visible
What is Aamlodipine and Olmesartan Medoxomil used for?

Aamlodipine and Olmesartan Medoxomil is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Aamlodipine and Olmesartan Medoxomil?

No. Aamlodipine and Olmesartan Medoxomil is brand-only with no generic equivalents currently in market.

How much does my plan pay for Aamlodipine and Olmesartan Medoxomil?

Across 329 Part D plans, Aamlodipine and Olmesartan Medoxomil averages $0.319/unit (NADAC). Lowest available: $0.319/unit. Highest in distribution: $0.319/unit.

Is Aamlodipine and Olmesartan Medoxomil on the FDA shortage list?

No. Aamlodipine and Olmesartan Medoxomil is not currently on the FDA Drug Shortage Database.

3 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.